Clinical Trial Update: Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating vorinostat with or without isotretinoin in pediatric patients with recurrent or refractory solid tumors, lymphoma, or leukemia; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Acute Promyelocytic Leukemia
• Atypical Teratoid Rhabdoid Tumor
• Burkitt Lymphoma
• Chronic Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Neuroblastoma

Drugs mentioned

• ISOTRETINOIN (Isotretinoin)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Status: COMPLETED